Market Place
Sourcing Support
Todos Medical Announces Insolvency Proceedings in Israel
22 Dec 2023 //
GLOBENEWSWIRE
Todos Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
26 Sep 2023 //
GLOBENEWSWIRE
Todos Announces Notice of Allowance From USPTO for Patent Application
30 Aug 2023 //
GLOBENEWSWIRE
Todos Medical Enters Into Letter of Intent for Provista Diagnostics
28 Mar 2023 //
GLOBENEWSWIRE
Todos Medical Begins Trading on the OTC Pink Marketplace
27 Mar 2023 //
GLOBENEWSWIRE
Todos Medical Supports Long COVID Awareness Day
15 Mar 2023 //
GLOBENEWSWIRE
Todos Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
13 Mar 2023 //
GLOBENEWSWIRE
Todos Medical Provides Corporate Update
23 Feb 2023 //
GLOBENEWSWIRE
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A Test
14 Feb 2023 //
GLOBENEWSWIRE
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
06 Dec 2022 //
GLOBENEWSWIRE
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations
29 Nov 2022 //
GLOBENEWSWIRE
Todos Medical to Attend World Antiviral Congress
22 Nov 2022 //
GLOBENEWSWIRE
Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement
16 Nov 2022 //
GLOBENEWSWIRE
Todos Terminates Tollovid™ Products License & Distribution Agreement T-Cell
10 Nov 2022 //
GLOBENEWSWIRE
Todos Medical Announces BioFuture™ NYC 2022 Presentation
04 Nov 2022 //
GLOBENEWSWIRE
Provista seeks US FDA emergency use authorization for PCR MonkeyPox Test
17 Oct 2022 //
PHARMABIZ
Todos Medical CLIA/CAP Lab Provista Submits EUA for MonkeyPox PCR Test to US FDA
14 Oct 2022 //
GLOBENEWSWIRE
Todos Medical advances Tollovir™: 3CL Clinical Trials to Phase 2
14 Oct 2022 //
GLOBENEWSWIRE
Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing
06 Oct 2022 //
GLOBENEWSWIRE
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA
30 Sep 2022 //
GLOBENEWSWIRE
Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease
27 Sep 2022 //
GLOBENEWSWIRE
Todos Medical Enters Into $50M Contract to Supply Tollovid™
22 Sep 2022 //
GLOBENEWSWIRE
Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™
16 Sep 2022 //
GLOBENEWSWIRE
Todos Medical Announces Preprint of Long COVID Case Study Participant
15 Sep 2022 //
GLOBENEWSWIRE
Todos Medical Initiates Validation Plan for PCR-based Polio Testing at CLIA/Cap
14 Sep 2022 //
GLOBENEWSWIRE
Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™
13 Sep 2022 //
GLOBENEWSWIRE
Todos CEO Discusses COVID Impact with Moneta Advisory Partner Marc LoPresti
09 Sep 2022 //
GLOBENEWSWIRE
Todos Medical Establishes Botanical Supplement Manufacturing Capabilities
31 Aug 2022 //
GLOBENEWSWIRE
Todos Announces Saliva-Only MonkeyPox Testing at CLIA/CAP
26 Aug 2022 //
GLOBENEWSWIRE
Todos Medical Initiates MonkeyPox Diagnostic Case Studies
23 Aug 2022 //
GLOBENEWSWIRE
Todos Announces Commercialization of MonkeyPox PCR Testing
22 Aug 2022 //
GLOBENEWSWIRE
Todos Medical Reports Second Quarter 2022 Financial Results
22 Aug 2022 //
GLOBENEWSWIRE
Todos Reports Pre-Print of Publication Detailing Tollovid Supplementation
15 Aug 2022 //
GLOBENEWSWIRE
Todos Medical Completes Trial Design for Tollovid™ Long COVID Clinical Study
11 Aug 2022 //
GLOBENEWSWIRE
Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels
10 Aug 2022 //
GLOBENEWSWIRE
Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing
08 Aug 2022 //
GLOBENEWSWIRE
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement
05 Aug 2022 //
GLOBENEWSWIRE
Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test
03 Aug 2022 //
GLOBENEWSWIRE
Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound
01 Aug 2022 //
GLOBENEWSWIRE
Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel
28 Jul 2022 //
GLOBENEWSWIRE
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid
22 Jul 2022 //
GLOBENEWSWIRE
Todos Medical Reports Case Study #7 in Acute and Long COVID
12 Jul 2022 //
GLOBENEWSWIRE
Todos Medical Announces Positive Biomarker Data from PII Trial of Tollovir
30 Jun 2022 //
GLOBENEWSWIRE
Todos Releases Prelim Data From IRB-Waived Tollovid Market Research Study
23 Jun 2022 //
GLOBENEWSWIRE
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors
21 Jun 2022 //
GLOBENEWSWIRE
Todos Medical Completes Validation of 27 Pathogen UTI PCR Panel
13 Jun 2022 //
GLOBENEWSWIRE
Todos Medical Reports Day 45 Update for Case Study #6
10 Jun 2022 //
GLOBENEWSWIRE
Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction
07 Jun 2022 //
GLOBENEWSWIRE
Todos Medical to Present at The LD Micro Conference
06 Jun 2022 //
GLOBENEWSWIRE
Todos Medical Announces Enrollment Complete for Confirmatory Cohort
03 Jun 2022 //
GLOBENEWSWIRE
Todos Medical Reports Day 26 Update For Case Study #4
01 Jun 2022 //
GLOBENEWSWIRE
Todos Medical to Present Final Data from the Tollovir PII Trial
27 May 2022 //
GLOBENEWSWIRE
Todos Medical Releases Corporate Update
27 May 2022 //
GLOBENEWSWIRE
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid
06 May 2022 //
GLOBENEWSWIRE
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid
02 May 2022 //
GLOBENEWSWIRE
3CL Pharma commences study of Tollovid for Covid-19
28 Apr 2022 //
PHARMACEUTICAL-TECHNOLOGY
Todos Medical Initiates IRB-Waived Tollovid Market Research Study
27 Apr 2022 //
GLOBENEWSWIRE
Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista
21 Apr 2022 //
GLOBENEWSWIRE
Todos Medical Reports 2nd Long COVID Case Study and Launches Website
20 Apr 2022 //
GLOBENEWSWIRE
Todos Medical Targets Athlete Support with Informed Sport Certification
19 Apr 2022 //
GLOBENEWSWIRE
